Loading company…
Riskpilot
← Back to search
Sign in
Get full access
FIKKAN PHARMA AS
AS
Active
Org 915077307
Sinsenveien 75B, 0586 Oslo
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2015
0 employees
www.fikkanpharma.com
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2025
NOK 819K
+23% vs 2024
EBITDA margin
78.5%
+26% vs 2024
Equity ratio
91.6%
Financial strength
Net profit 2025
NOK 1M
+5% vs 2024
EBITDA — year on year
NOK millions
1M
1M
1M
0M
0M
0M
2021
1M
+100%
2022
1M
0%
2023
1M
0%
2024
1M
0%
2025
Key figures
Annual report 2025
Revenue
NOK 819K
+23%
EBITDA
NOK 643K
+26%
Net profit
NOK 1M
+5%
Total assets
NOK 3,9M
+40%
Equity
NOK 3,5M
+40%
Employees
0
—
Company information
Legal name
FIKKAN PHARMA AS
Org number
915077307
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
6. mars 2015
Share capital
NOK 30 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Daglig leder alene. Styrets leder alene.
Company purpose
Yte bistand innen forretningsutvikling, herunder å erverve eierinteresser og egenkapitalinstrumenter i virksomheter.
Contact
Address
Sinsenveien 75B, 0586 Oslo
Website
www.fikkanpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Oslo
All Norway companies
Revenue
NOK millions
0M
0M
1M
1M
1M
0M
2021
1M
2022
1M
2023
1M
2024
1M
2025
EBITDA
NOK millions
0M
0M
1M
1M
1M
0M
2021
1M
2022
1M
2023
1M
2024
1M
2025
Income statement
NOK thousands
Item
2021
2022
2023
2024
2025
Revenue
346
668
857
666
819
Staff expenses
−0
−0
−0
−0
−0
EBITDA
188
524
697
509
643
Depreciation & amort.
−0
−0
−0
−0
−0
EBIT
188
524
697
509
643
Net financials
−4
1
50
565
525
Profit before tax
184
525
747
1 074
1 168
Tax
41
116
152
115
159
Net profit
143
410
594
959
1 009
Balance sheet
NOK thousands
Item
2021
2022
2023
2024
2025
Total assets
1 597
2 097
1 896
2 770
3 871
Equity
1 453
1 862
1 577
2 536
3 545
Long-term debt
0
0
0
0
0
Short-term debt
145
234
319
234
325
Total debt
145
234
319
234
325
Financial ratios
5-year trend
EBITDA margin
78.5%
This company
15.8%
Market median
+397% vs market
2021
2025
Equity ratio
91.6%
This company
38.2%
Market median
+140% vs market
2021
2025
Return on equity
28.5%
This company
18.4%
Market median
+55% vs market
2021
2025
Net profit margin
123.3%
This company
8.1%
Market median
+1422% vs market
2021
2025
Asset turnover
0.21×
This company
1.12×
Market median
-81% vs market
2021
2025
Debt / equity
0.09×
This company
0.62×
Market median
+85% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (1)
JF
Jan Fikkan
Chairman
2015
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of FIKKAN PHARMA AS also hold positions in
0
other companies.
Person
Role here
Other companies
Jan Fikkan
Chairman
0 companies